Литература
1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140-205. doi: 10.1016/j.atherosclerosis.2019.08.014
2. Martin AC, Bell DA, Brett T, Watts G F. Beyond cascade screening : detection of familial hypercholesterolaemia at childhood immunization and other strategies. Curr Op Lipidol. 2017; 28 (4): 321–327.
3. Минушикна Л.О., Зотова И.В., Чумакова О.С, Королева О.С., Иосава И.К., Спешилов Г.И., и др. Диагностика сердечно-сосудистых заболеваний преимущественно генетического происхождения. Москва, 2018, с. 207.
4. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016, 37(39):2999-3058.
5. Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P et al. SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16:541-549.
6. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017; 70(14): 1785-1822. doi: 10.1016/j.jacc.2017.07.745.
7. Kramer AI, Trinder M, Brunham LR. Estimating the Prevalence of Familial Hypercholesterolemia in Acute Coronary Syndrome: A Systematic Review and Meta-analysis. Can J Cardiol. 2019; 35(10): 1322-1331. doi: 10.1016/j.cjca.2019.06.01.
8. Sun D, Cao YX, Li S, Guo YL, Wu NQ, Gao Y et al. A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia. Clin Cardiol. 2019; 42(10): 988-994. doi: 10.1002/clc.23251.
9. Chan DC, Pang J, Hooper AJ, Bell DA, Burnett JR, Watts GF. Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic? Clin Chem. 2019; 65(10): 1258-1266. doi: 10.1373/clinchem.2019.306738.
10. Dyrbuś K, Gąsior M, Desperak P, Osadnik T, Nowak J, Banach M. The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis. 2019; 288:33-41. doi: 10.1016/j.atherosclerosis.2019.06.899.
11. Iyen B, Qureshi N, Kai J, Akyea RK, Leonardi-Bee J, Roderick P et al. Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study. Atherosclerosis. 2019; 287: 8-15. doi: 10.1016/j.atherosclerosis.2019.05.017.
12. Wang Y, Li Y, Liu X, Tu R, Zhang H, Qian X et al. The prevalence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition. BMC Public Health. 2019; 19(1): 837. doi: 10.1186/s12889-019-7212-4.
13. Bérard E, Bongard V, Haas B, Dallongeville J, Moitry M, Cottel et al. Prevalence and Treatment of Familial Hypercholesterolemia in France. Can J Cardiol. 2019; 35(6):744-752. doi: 10.1016/j.cjca.2019.02.013.
14. Lunegova OS, Mirrakhimov AE, Hodzhiboboev E, Bektasheva EE, Neronova KV, Toktomamatov UM et al. The frequency of familial hypercholesterolemia amongst patients in the outpatient clinic of the tertiary specialized cardiology center in Kyrgyzstan. Atheroscler Suppl. 1. 2019; 36: 1-5. doi: 10.1016/j.atherosclerosis sup.2019.01.001.
15. Mirzaee S, Choy KW, Doery JCG, Zaman S, Cameron JD, Nasis A.The tertiary hospital laboratory; a novel avenue of opportunistic screening of familial hypercholesterolemia. Int J Cardiol Heart Vasc. 2019; 23:100354. doi: 10.1016/j.ijcha.2019.100354.
16. Pang J, Chan DC, Hu M, Muir LA, Kwok S, Charng MJ et al. Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study". J Clin Lipidol. 2019; 13(2):287-300. doi: 10.1016/j.jacl.2019.01.009.
17. Langlois MR, Descamps OS, van der Laarse A, Weykamp C, Baum H et al. EAS-EFLM Collaborative Project. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis. 2014; 233(1): 83-90. doi: 10.1016/j.atherosclerosis.2013.12.016.